BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 28024498)

  • 21. DNA repair gene expressions are related to bone marrow cellularity in myelodysplastic syndrome.
    Ribeiro HL; Maia ARS; de Oliveira RTG; Costa MB; Farias IR; de Paula Borges D; de Sousa JC; Magalhães SMM; Pinheiro RF
    J Clin Pathol; 2017 Nov; 70(11):970-980. PubMed ID: 28554891
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pyrosequencing quantified methylation level of miR-124 predicts shorter survival for patients with myelodysplastic syndrome.
    Wang H; Zhang TT; Jin S; Liu H; Zhang X; Ruan CG; Wu DP; Han Y; Wang XQ
    Clin Epigenetics; 2017; 9():91. PubMed ID: 28861128
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Expression and Function of miR-99a-5p in Bone Marrow of Patients with MDS].
    LE Y; Zhang XP; Xiong YQ; Li HY; Zhao WH; Long Y; Luo J; Cheng P; Liu ZF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Feb; 27(1):134-140. PubMed ID: 30738460
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Over-expression of miR-196b-5p is significantly associated with the progression of myelodysplastic syndrome.
    Wen J; Huang Y; Li H; Zhang X; Cheng P; Deng D; Peng Z; Luo J; Zhao W; Lai Y; Liu Z
    Int J Hematol; 2017 Jun; 105(6):777-783. PubMed ID: 28224273
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of DNA demethylation effects induced by 5-Aza-2'-deoxycytidine in patients with myelodysplastic syndrome.
    Mund C; Hackanson B; Stresemann C; Lübbert M; Lyko F
    Cancer Res; 2005 Aug; 65(16):7086-90. PubMed ID: 16103056
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Methylation of Wnt antagonist genes: a useful prognostic marker for myelodysplastic syndrome.
    Wang H; Fan R; Wang XQ; Wu DP; Lin GW; Xu Y; Li WY
    Ann Hematol; 2013 Jan; 92(2):199-209. PubMed ID: 23093371
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of miR-223 on cellular behaviour in non-5q myelodysplastic syndromes through targeting RPS14.
    Nie Y; Wang S; Yu Y; Zuo X; Xiong B
    Pathology; 2020 Aug; 52(5):552-560. PubMed ID: 32571542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of type 1 insulin-like growth factor receptor in marrow nucleated cells in malignant hematological disorders: correlation with apoptosis.
    Qi H; Xiao L; Lingyun W; Ying T; Yi-Zhi L; Shao-Xu Y; Quan P
    Ann Hematol; 2006 Feb; 85(2):95-101. PubMed ID: 16328478
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction of gene expression by 5-Aza-2'-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and -independent mechanisms.
    Schmelz K; Sattler N; Wagner M; Lübbert M; Dörken B; Tamm I
    Leukemia; 2005 Jan; 19(1):103-11. PubMed ID: 15510208
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro study of biological characteristics of mesenchymal stem cells in patients with low-risk myelodysplastic syndrome.
    Zhang YZ; Zhao DD; Han XP; Jin HJ; Da WM; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):813-8. PubMed ID: 18718067
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic microRNAs in myelodysplastic syndrome.
    Erdogan B; Facey C; Qualtieri J; Tedesco J; Rinker E; Isett RB; Tobias J; Baldwin DA; Thompson JE; Carroll M; Kim AS
    Exp Hematol; 2011 Sep; 39(9):915-926.e2. PubMed ID: 21703983
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of heme oxygenase-1 in demethylating effects on SKM-1 cells induced by decitabine.
    Gao R; Ma D; Wang P; Sun J; Wang JS; Fang Q
    Genet Mol Res; 2015 Dec; 14(4):17788-98. PubMed ID: 26782424
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias.
    Leone G; Teofili L; Voso MT; Lübbert M
    Haematologica; 2002 Dec; 87(12):1324-41. PubMed ID: 12495905
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased apoptosis in mononucleated cells but not in CD34+ cells in blastic forms of myelodysplastic syndromes.
    Berger G; Hunault-Berger M; Rachieru P; Fontenay-Roupie M; Baranger L; Ifrah N; Zandecki M
    Hematol J; 2001; 2(2):87-96. PubMed ID: 11424000
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies.
    Hackanson B; Robbel C; Wijermans P; Lübbert M
    Ann Hematol; 2005 Dec; 84 Suppl 1():32-8. PubMed ID: 16292549
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group.
    Lübbert M; Suciu S; Baila L; Rüter BH; Platzbecker U; Giagounidis A; Selleslag D; Labar B; Germing U; Salih HR; Beeldens F; Muus P; Pflüger KH; Coens C; Hagemeijer A; Eckart Schaefer H; Ganser A; Aul C; de Witte T; Wijermans PW
    J Clin Oncol; 2011 May; 29(15):1987-96. PubMed ID: 21483003
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interleukin-17 enhances the production of interferon-γ and tumour necrosis factor-α by bone marrow T lymphocytes from patients with lower risk myelodysplastic syndromes.
    Zhang Z; Li X; Guo J; Xu F; He Q; Zhao Y; Yang Y; Gu S; Zhang Y; Wu L; Chang C
    Eur J Haematol; 2013 May; 90(5):375-84. PubMed ID: 23331180
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Preliminary study on difference of Id4 gene methylation in various types of myelodysplastic syndromes].
    Zhao Y; Bo J; Dou LP; Jing Y; Wang SH; Wang QS; Li HH; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):618-20. PubMed ID: 19549375
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aberrant microRNA expression pattern in myelodysplastic bone marrow cells.
    Hussein K; Theophile K; Büsche G; Schlegelberger B; Göhring G; Kreipe H; Bock O
    Leuk Res; 2010 Sep; 34(9):1169-74. PubMed ID: 20627384
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of Toll-like receptor 9 in bone marrow cells of myelodysplastic syndromes is down-regulated during transformation to overt leukemia.
    Kuninaka N; Kurata M; Yamamoto K; Suzuki S; Umeda S; Kirimura S; Arai A; Nakagawa Y; Suzuki K; Kitagawa M
    Exp Mol Pathol; 2010 Apr; 88(2):293-8. PubMed ID: 20132814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.